These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome. Kong J, Gao MG, Qin YZ, Wang Y, Yan CH, Sun YQ, Chang YJ, Xu LP, Zhang XH, Liu KY, Huang XJ, Zhao XS. BMC Cancer; 2022 Jan 03; 22(1):11. PubMed ID: 34979982 [Abstract] [Full Text] [Related]
7. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Britt A, Mohyuddin GR, McClune B, Singh A, Lin T, Ganguly S, Abhyankar S, Shune L, McGuirk J, Skikne B, Godwin A, Pessetto Z, Golem S, Divine C, Dias A. Leuk Res; 2020 Aug 03; 95():106402. PubMed ID: 32590108 [Abstract] [Full Text] [Related]